| Description | CGP-28014 is an inhibitor of catechol-O-methyltransferase. CGP-28014 increases the renal excretion of both dopamine and dihydroxyphenylacetic acid (DOPAC) but does not affect renal sodium handling indicating a different mechanism of action. CGP-28014 significantly reduced the levels of homovanillic acid (HVA), but did not modify DA and 3,4-dihydroxyphenylacetic acid (DOPAC). |
| molecular weight | 221.3 |
| Molecular formula | C12H19N3O |
| CAS | 111757-17-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Kambur O, Talka R, Ansah OB, Kontinen VK, Pertovaara A, Kalso E, Männistö PT. Inhibitors of catechol-O-methyltransferase sensitize mice to pain. Br J Pharmacol. 2010 Dec;161(7):1553-65. doi: 10.1111/j.1476-5381.2010.00999.x. PubMed PMID: 20726980; PubMed Central PMCID: PMC3010567. 2. Hansell P, Odlind C, Männistö PT. Different renal effects of two inhibitors of catechol-O-methylation in the rat: entacapone and CGP 28014. Acta Physiol Scand. 1998 Apr;162(4):489-94. PubMed PMID: 9597116. 3. Männistö PT. Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors. Adv Pharmacol. 1998;42:324-8. PubMed PMID: 9327906. 4. Psylla M, Günther I, Antonini A, Vontobel P, Reist HW, Zollinger A, Leenders KL. Cerebral 6-[18F]fluoro-L-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition. Brain Res. 1997 Aug 29;767(1):45-54. PubMed PMID: 9365014. |